3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Melanoma
37
Neoplasms
30
Colorectal Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
5
Neoplasm Metastasis
5
Rectal Neoplasms
3
Multiple Myeloma
3
Leukemia, Myeloid, Acute
3
Glioma
3
Colonic Neoplasms
3
Breast Neoplasms
3
Biliary Tract Neoplasms
3
Thyroid Neoplasms
2
Sarcoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Oligodendroglioma
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Glioblastoma
2
Cholangiocarcinoma
2
Brain Neoplasms
2
Astrocytoma
2
Adenocarcinoma of Lung
2
Adenocarcinoma
2
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Solid Tumors
1
Skin Neoplasms
1
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
trametinib
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled